What's Hot at EULAR 2013 Medscape "Biosimilars are on the verge of being licensed in Europe, and there will be discussions about infliximab and rituximab — the 2 most prominent ones," said Dr. Müller-Ladner, from Justus Libig University in Giessen, Germany. The scientific program ... |
